Pfizer could haul in $3.5B in 2021 from COVID-19 vaccine: analyst Planes, trucks and ultracold boxes: Pfizer preps massive COVID-19 vaccine distribution effort CDC warns of "distressing trend" with increased COVID-19 cases across nearly 75% of the country Patient death casts a shadow on AstraZeneca's COVID-19 trial: report AstraZeneca tipped to restart COVID-19 vaccine trial this week: report Does Roche's Actemra work in COVID-19? New studies once again paint mixed picture Biopharma roundup: California sets up expert panel to vet vaccines Healthcare roundup: CVS launches education resources on drug abuse for virtual classrooms How COVID-19 shifted healthcare executives' technology priorities and what to expect in 2021 IQVIA nudges up guidance on bullish outlook, but R&D services still dragging on COVID-19 challenges Tenet Healthcare works its playbook to drive Q3 recovery amid COVID challenges One pandemic, $2 billion, 3 months: Top COVID-19 player Thermo Fisher posts hefty Q3 revenue Eli Lilly may face FDA warning letter after recent inspection at COVID-19 antibody plant found more issues: report Stanford Medicine launches home COVID-19 testing study covering greater San Francisco Featured Story | By Arlene Weintraub Pfizer is emerging as the clear frontrunner in the race to get a COVID-19 vaccine to market, but what will that be worth to investors? Analysts at SVB Leerink expect Pfizer and partner BioNTech will grab 50% of the market to start, but competitive pressure—and not just in the COVID market—will limit its upside. read more |
| |
|---|
|
| | Webinar: The Power of Virtual Health Assessments during COVID Tuesday, October 27 | 11am ET / 8am PT COVID-19 has forced us to rethink how we effectively support members, and manage quality improvement and risk adjustment initiatives. This webinar provides a look at how Virtual Health Assessments improve healthcare outcomes for members, providers, and payers. Explore how Advantmed’s telehealth solution supports quality improvement and risk adjustment. Register Today. |
Top Stories By Eric Sagonowsky As Pfizer’s COVID-19 vaccine comes into the home stretch on the R&D side, the drugmaker is scaling up an ambitious supply chain and distribution system aimed at delivering hundreds of millions of doses around the world as quickly as possible. read more By Robert King COVID-19 cases are on the rise practically everywhere, as cases are increasing across 75% of the country, according to the CDC. read more By Amirah Al Idrus A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday. Despite the death, the study will carry on as normal, Reuters said. read more By Nick Paul Taylor AstraZeneca could resume the U.S. clinical trial of its COVID-19 vaccine this week, according to a Reuters report. The trial has been paused since early September while the FDA reviews the safety of the vaccine in light of a reported case of a rare spinal inflammatory disorder in the wider program. read more By Angus Liu Roche’s arthritis therapy Actemra was one of the earliest-identified COVID-19 treatment prospect. But three new clinical studies have shown mixed results with seemingly contradictory results, leaving one infectious disease expert ruling that existing data do not support routine use of the drug in COVID-19. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner A patient given a placebo in AstraZeneca's phase 3 vaccine trial died, Reuters reports. California will run independent reviews of FDA-approved vaccines. Pfizer could snare $3.5 billion in 2021 vaccine sales, analysts predict. Aridis aims to test its inhaled antibody in humans next year. And Stanford Medicine launched a massive testing program in San Francisco. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Heather Landi When the COVID-19 pandemic hit earlier this year, health system executives had to shift their priorities to fast-track innovations such as virtual care services and artificial intelligence tools. Here's how the COVID-19 pandemic changed healthcare executives' focus on technology and what to expect in 2021. read more By Ben Adams IQVIA is still steering around COVID-19 roadblocks with its R&D business still posting a loss, but other segments are recovering as it ups its full-year guidance. read more By Tina Reed As Tenet Healthcare reported its third-quarter earnings on Tuesday, CEO Ronald A. Rittenmeyer said it shaped up to be "in many ways more challenging than the second, with COVID positive inpatient census surging by approximately 64% in our markets in late July and August." read more By Conor Hale As a top producer of diagnostic test kits, laboratory hardware and supplies, Thermo Fisher Scientific has been a major player in the global response to the COVID-19 pandemic almost from the start—and now, the company has shown exactly how major. read more By Kyle Blankenship Eli Lilly's chances at an emergency use authorization for its COVID-19 antibody took a big hit after a major trial was stopped for safety issues and the FDA flagged a site producing the therapy for data handling concerns. Now, the FDA is back for more, and it could spell even bigger problems. read more By Conor Hale Stanford University and its school of medicine have launched plans to survey the population of greater San Francisco for COVID-19, in an effort to build an early warning system for future outbreaks. read more |
